BRD2 and familial pancreatic carcinoma: One of these studies most closely resembled this study by focusing on potentially resectable pancreatic cancer, therefore including borderline and locally advanced cases in the NAT pathway to capture the effect of conversion to resectability on overall pathway analysis [9].